Novo Nordisk says the $69 investment in its Danish plant will convert capacity ready for its new GLP-1 analogue and is a further commitment to Danish manufacturing.
New auto-injector technology that is user-friendly and capable of delivering high viscosity drugs may be the next big thing for pharma and biotech companies pushing further into niche biologics and biosimilars.
Injex says it is looking for partners to prefill its device and Glide will develop Pfenex’s anthrax vaccine using its solid-dose injector – welcome to our needle-free drug delivery round-up.
Efforts to update SUPAC guidance on immediate and modified release dosage forms will end in faster approvals, if regulatory and financial hurdles can be overcome, says expert.
Despite offers from Amgen and Novartis reportedly worth up to $2bn, Hikma announced last week it will keep its profitable and growing injectable business.
Following its acquisition by Mayne Pharma, Metrics says it is to offer proprietary pellet form technology for advanced drug release and to increase bioavailability.
French biotech company ANGANY Genetics says its new platform can provide pharma companies low cost and high quality recombinant allergens for drug testing purposes.
Novaliq has raised funds to further development of its bioavailability boosting delivery technology and take its candidate dry eye drug into Phase I trials.
As it inks a major commercial supply agreement, Unilife says its EZMix dual-chamber syringe will significantly cut reconstitution steps in combination therapy delivery.
Jerusalem, Israel-based drugmaker Oramed Pharmaceuticals has been granted patent approval for its oral insulin technology by the Japanese Patent office.
Lilly says another investment in its Indianapolis facility will add a second insulin cartridge-filling line and is driven by the increasing prevalence of diabetes.
BD says a brand new facility and sustainable pricing will allow the company to compete as it enters the generics market following FDA approval of its first injectable drug.
Drug solubility science, technology and solutions will take centre stage at “The Bioavailability Challenge” a free to attend online event in-Pharmatechnologist.com is hosting on Wednesday, March 20.
Catalent says it has acquired a Chinese softgel producer to expand its drug delivery offerings and expects more investments to come as part of a two-pronged plan into China.
Novo Nordisk says “there is still room for improvement” in the development and delivery of insulin as it awaits FDA approval of its challenge to Lantus.
A new partnership between a niche cancer drug discovery company and biotech powerhouse Celgene could pave the way for the future of cancer drug discovery and delivery.
Good ideas in drug delivery will continue to attract investment though the increasing cost of clinical trials does pose a difficulty according to MIT Professor Robert Langer.
Pantarhei Bioscience has sold in Estetra, its oral contraceptive development JV, to partner Uteron Pharma and will use the proceeds to fund further development.
Aesica and EmulTech claim a new sterile formulation technology could help drugmakers resurrect abandoned projects and extend the lifespan of marketed medicines.
Hospira says bringing medical device manufacturing operations up to code will take 'a lot of work' after Lake Forest, Illinois plant is hit with US FDA Form 483.
Protalix Biotherapeutics is attempting to use its US FDA-approved Gaucher's disease treatment as a proof of concept and springboard for its plant-based cell manufacturing technology.
EpiVax says combining its immune 'off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.
With Angiomax potentially going generic in 2015, The Medicines Company has collaborated with Alnylam over a 'pragmatic' high cholesterol drug to aid future growth.